2085 related articles for article (PubMed ID: 16400749)
1. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
Prescrire Int; 2006 Jun; 15(83):94-7. PubMed ID: 16764097
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
Prescrire Int; 2005 Dec; 14(80):215-7. PubMed ID: 16400742
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy of colon cancer: lymph node involvement without metastases.
Prescrire Int; 2006 Jun; 15(83):109-1. PubMed ID: 16764102
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
Prescrire Int; 2002 Apr; 11(58):44-7. PubMed ID: 11987311
[TBL] [Abstract][Full Text] [Related]
7. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
9. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
François E; Berdah JF; Chamorey E; Lesbats G; Teissier E; Codoul JF; Badetti JL; Hébert C; Mari V
Cancer Chemother Pharmacol; 2008 Nov; 62(6):931-6. PubMed ID: 18273618
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
[TBL] [Abstract][Full Text] [Related]
11. [IFL].
Yamazaki K; Yoshino T; Boku N
Gan To Kagaku Ryoho; 2006 Jul; 33(7):907-10. PubMed ID: 16835478
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
13. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
Miyazaki Y; Harada T; Akase T; Arakawa I; Inoue T
Clin Ther; 2009; 31 Pt 2():2433-41. PubMed ID: 20110051
[TBL] [Abstract][Full Text] [Related]
14. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease.
Prescrire Int; 2011 Feb; 20(113):46-9. PubMed ID: 21488594
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
[TBL] [Abstract][Full Text] [Related]
18. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
19. Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer.
Hsiao SC; Lin JF; Chuang MT; Lee YA; Wu DL
Int Surg; 2009; 94(4):298-303. PubMed ID: 20302025
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
Prescrire Int; 2001 Apr; 10(52):41-3. PubMed ID: 11718156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
